Project Type: Clinical trial
Status: Open – recruiting now
About the project: This study is evaluating an investigational medication called cannabidiol (CBD) to see how safe and how well CBD works in patients with Parkinson’s who are experiencing hallucinations or delusions. CBD is the non-addictive component of the cannabis plant with potential antipsychotic properties.
What’s involved?: If you agree to take part, you will join one of two treatment groups for 12 weeks: a placebo (‘dummy’ drug) group OR a medication (Cannabidiol) group.
You will have planned visits and phone calls with the Neuroprogressive and Dementia Network Clinical Research team, who will ask you about your symptoms, how you feel and your study treatment. A family member or person who knows you well will also be asked to answer questions about your symptoms and about how they are feeling.
The study visits will be conducted at the Clinical Research Facility at the Western General Hospital and taxi transport can be organised.
Who is eligible to take part?: To take part in the trial, you will be aged over 40 years and have a diagnosis of Parkinson’s Disease. You will also be experiencing symptoms such as hallucinations or delusions.
For more information: Please contact the Neuroprogressive and Dementia Network Clinical Research team:
Jess Crossan, Emma Fleming or Gordon Duncan (PI)
Email: loth.sdcrn@nhs.scot or gordon.duncan2@nhs.scot
Tel: 0131 537 3804
Websites
https://services.nhslothian.scot/neuroprogressiveanddementianetwork/can-pdp/
https://www.kcl.ac.uk/research/cannabidiol-for-parkinsons-disease-psychosis-can-pdp-trial